Can mirtazapine cause tachycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Mirtazapine Increase Heart Rate?

Yes, mirtazapine can cause tachycardia, particularly in overdose situations, though this effect is generally mild and self-limited at therapeutic doses.

Evidence from FDA Drug Labeling

The FDA drug label explicitly documents tachycardia as an adverse effect of mirtazapine 1. In clinical trials, mirtazapine was associated with a mean increase in heart rate of 3.4 bpm compared to 0.8 bpm for placebo 1. While this increase is modest at therapeutic doses, the clinical significance becomes more apparent in specific contexts.

Tachycardia Risk Profile

At Therapeutic Doses

  • Mean heart rate increase of approximately 3.4 bpm above baseline 1
  • Generally well-tolerated without clinical intervention required
  • The effect appears early in treatment and may persist

In Overdose Situations

Tachycardia becomes more clinically significant with supratherapeutic doses:

  • Tachycardia occurred in 30-33% of overdose patients in observational studies 2, 3
  • In FDA postmarketing surveillance, tachycardia is explicitly listed as a sign of overdose 1
  • Case reports document first-degree AV block with paradoxical sinus tachycardia in overdose scenarios 4
  • One fatal case reported ventricular tachycardia leading to cardiac arrest when mirtazapine was combined with sertraline 5

Cardiac Safety Considerations

QT Prolongation Risk

The FDA label warns that mirtazapine can cause QT prolongation and Torsades de Pointes, particularly in overdose or when combined with other QTc-prolonging medications 1. Exercise caution in patients with:

  • Known cardiovascular disease
  • Family history of QT prolongation
  • Concomitant use of other QTc-prolonging drugs

Mechanism

Recent research suggests mirtazapine antagonizes human cardiac H1-histamine receptors at therapeutic concentrations, which may contribute to cardiac effects 6.

Clinical Management Algorithm

For patients starting mirtazapine:

  1. Obtain baseline heart rate and ECG if cardiovascular risk factors present
  2. Monitor heart rate during titration phase (first month)
  3. Be aware that tachycardia typically occurs early and may spontaneously resolve
  4. Consider dose adjustment or alternative therapy if persistent tachycardia (HR >100 bpm for >3 consecutive days) causes symptoms

For suspected overdose:

  1. Immediately assess for tachycardia, altered mental status, and QTc prolongation
  2. Obtain ECG to evaluate for conduction abnormalities
  3. Monitor continuously as serious arrhythmias (VT, Torsades) have been reported 1, 5
  4. Contact Poison Control (1-800-222-1222) as no specific antidote exists 1

Important Caveats

  • The majority of serious cardiac events (QT prolongation, Torsades de Pointes, ventricular tachycardia) occurred in overdose situations or with drug interactions 1
  • Single-agent mirtazapine overdoses are generally well-tolerated with mild tachycardia and no deaths reported in large case series 2, 3
  • Co-ingestion with other medications significantly increases toxicity risk 2
  • Recent FAERS database analysis identified prolonged QT interval as a previously underreported adverse event 7

Bottom line: While mirtazapine causes a modest increase in heart rate at therapeutic doses, clinically significant tachycardia primarily occurs in overdose or when combined with other cardiotoxic medications. Monitor appropriately based on individual cardiovascular risk factors.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.